---
layout: splash
title: 엔케이맥스 (182400)
excerpt: 엔케이맥스의 최근 공시, 수익률, 주요 재무/기술 지표
header:
  overlay_color: "#333"
  show_overlay_excerpt: false
categories:
- KOSDAQ
- Q:제약
keywords: 엔케이맥스, 182400
---

| **종가** | **전일대비** | **업종** | **PER** | **PBR** | **DIV** |
| -------: | -----------: | -------: | ------: | ------: | ------: |
| 2,020 | 0.0<small>%</small> | Q:제약 | 31.1 | 1.5 | - |

<!-- more -->


> **기업 개요**<a id="company"></a>

| <span style="white-space:nowrap;">**섹터**</span> | Q:제약 / 기초 의약물질 및 생물학적 제제 제조업 |
| <span style="white-space:nowrap;">**산업**</span> | 연구용 시약, NK Vue® KIT, SuperNK |
| <span style="white-space:nowrap;">**상장**</span> | KOSDAQ / 2015년 10월 23일 상장 / 12월 결산 |
| <span style="white-space:nowrap;">**대표자**</span> | 박상우 |
| <span style="white-space:nowrap;">**홈페이지**</span> | [http://www.nkmax.com](http://www.nkmax.com){:target="_blank"} |


> **최근 7일 DART 신규 공시**<a id="dart"></a>

| **일자** |      | **보고서명** |
| :------- | :--- | :----------- |
| 05&#x2011;16 | | [분기보고서 (2024.03)](https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20240516001824){:target="_blank"} |
| 05&#x2011;14 | | [[기재정정]소송등의제기ㆍ신청(경영권분쟁소송)              (직무집행정지가처분신청)](https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20240514900034){:target="_blank"} |


> **주가 흐름**<a id="price"></a>

![182400](/stock/images/182400.png){: .align-center}


> **주요 가격 변동 지표**<small>[^fn_price_metric]</small>

| **종가** | **전일대비** | **5일** | **20일** | **60일** | **120일** |
| -------: | -----------: | ------: | -------: | -------: | --------: |
| 2,020 | 0.0<small>%</small> | 0.0<small>%</small> | 0.0<small>%</small> | <span style="color: cornflowerblue">-19.2<small>%</small></span> | <span style="color: cornflowerblue">-70.9<small>%</small></span> |
| **1년** | **편차** | **샤프** | **MDD** | **AvDD** | **MARr** |
| <span style="color: cornflowerblue">-65.2<small>%</small></span> | 85.7<small>%</small> | -0.76 | -79.9<small>%</small> | -32.7<small>%</small> | 0.8 |


> **주요 재무 지표**<small>[^fn_finance_metric]</small>

| **업종**<small>[^fn_sector_abbr]</small> | **PER** | **PBR** | **DIV** | **평가**<small>[^fn_finance_basic_tags]</small> |
| :--------------------------------------- | ------: | ------: | ------: | ----------------------------------------------: |
| Q:제약 | 31.1 | 1.5 | - | - |



{% include /commons/ads/adsense.html %}

> **세부 재무/투자 정보 제공 사이트**

| [네이버](https://m.stock.naver.com/domestic/stock/182400/finance/summary){:target="_blank"}<sup><small>모바일</small></sup> | [네이버](https://finance.naver.com/item/coinfo.naver?code=182400){:target="_blank"} | [FnGuide](https://comp.fnguide.com/SVO2/ASP/SVD_Invest.asp?gicode=A182400&MenuYn=Y){:target="_blank"} |
| :---: | :---: | :---: |
| [와이즈리포트](https://comp.wisereport.co.kr/company/c1040001.aspx?cmp_cd=182400){:target="_blank"} | [밸류라인](https://www.valueline.co.kr/finance/summary/182400){:target="_blank"} | [한국경제](https://markets.hankyung.com/stock/182400/financial-summary){:target="_blank"} |


> **주요 기술 지표**<small>[^fn_tech_metric]</small>


![182400](/stock/images/182400_tech.png){: .align-center}

| **기술 지표** | **1년** | **편차** | **샤프** | **MDD** | **AvDD** |
| :------------ | ------: | -----------: | -------: | ------: | -------: |
| 거치식 | -65.2<small>%</small> | 85.7<small>%</small> | -0.76 | -79.9<small>%</small> | -32.7<small>%</small> |
| 적립식[^fn_tech_metric_dca] | -49.2<small>%</small> | 84.6<small>%</small> | -0.58 | -74.8<small>%</small> | -30.6<small>%</small> |
| Sig. M[^fn_tech_metric_sigm] | -18.3<small>%</small> | 52.8<small>%</small> | -0.35 | -45.3<small>%</small> | -23.1<small>%</small> |
| SMA<small><sub>(5)</sub></small>[^fn_tech_metric_sma_i] | -40.6<small>%</small> | 47.9<small>%</small> | -0.85 | -55.6<small>%</small> | -33.2<small>%</small> |
| SMA<small><sub>(20)</sub></small>[^fn_tech_metric_sma_i] | -32.7<small>%</small> | 40.5<small>%</small> | -0.81 | -41.8<small>%</small> | -23.7<small>%</small> |
| SMA<small><sub>(60)</sub></small>[^fn_tech_metric_sma_i] | -15.5<small>%</small> | 40.4<small>%</small> | -0.38 | -39.5<small>%</small> | -27.1<small>%</small> |
| SMA<small><sub>(120)</sub></small>[^fn_tech_metric_sma_i] | -32.2<small>%</small> | 38.3<small>%</small> | -0.84 | -43.1<small>%</small> | -26.5<small>%</small> |
| SMA<small><sub>(240)</sub></small>[^fn_tech_metric_sma_i] | -20.0<small>%</small> | 39.6<small>%</small> | -0.50 | -31.8<small>%</small> | -21.1<small>%</small> |
| MACD[^fn_tech_metric_macd] | -34.8<small>%</small> | 49.8<small>%</small> | -0.70 | -56.4<small>%</small> | -21.2<small>%</small> |


> **주가 흐름 유사 종목**<a id="corr"></a><small>[^fn_corr_long]</small>

![182400](/stock/images/182400_corr.png){: .align-center}

|       | [엘앤씨바이오](/290650/) | [코오롱인더](/120110/) | [HD현대미포](/010620/) |
| :---: | :------------------------------------: | :------------------------------------: | :------------------------------------: |
|       | [롯데정밀화학](/004000/) | [네오위즈](/095660/) | [명신산업](/009900/) |


> **가상 레버리지 상품에 투자했다면**<a id="2x"></a><small>[^fn_lev]</small>

![182400](/stock/images/182400_2x.png){: .align-center}


> **관련 정보**

- [Q:제약 업종 목록](/stats/sector/kosdaq_업종_제약_종목/){: .btn .btn--info}

{% include commons/footnotes.md %}